Verve Therapeutics Inc (VERV)
6.37
+0.29
(+4.77%)
USD |
NASDAQ |
May 09, 16:00
6.39
+0.02
(+0.31%)
After-Hours: 20:00
Verve Therapeutics Cash from Operations (TTM): -143.54M for March 31, 2024
Cash from Operations (TTM) Chart
Historical Cash from Operations (TTM) Data
| Date | Value |
|---|---|
| March 31, 2024 | -143.54M |
| December 31, 2023 | -149.55M |
| September 30, 2023 | -141.76M |
| June 30, 2023 | -159.12M |
| March 31, 2023 | -137.92M |
| December 31, 2022 | -122.33M |
| September 30, 2022 | -117.48M |
| Date | Value |
|---|---|
| June 30, 2022 | -109.66M |
| March 31, 2022 | -96.25M |
| December 31, 2021 | -77.88M |
| September 30, 2021 | -64.81M |
| June 30, 2021 | -49.78M |
| March 31, 2021 | -43.58M |
| December 31, 2020 | -35.26M |
Cash From Operations Definition
Cash flow from operations is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall operating activities of the company. A few examples of operating activities include change in receivables, change in inventories, and changes in current assets.
Cash from Operations (TTM) Range, Past 5 Years
-159.12M
Minimum
Jun 2023
-35.26M
Maximum
Dec 2020
-103.50M
Average
-113.57M
Median
Cash from Operations (TTM) Benchmarks
| Acorda Therapeutics Inc | -13.98M |
| Eli Lilly and Co | 3.676B |
| Beam Therapeutics Inc | -139.13M |
| Intellia Therapeutics Inc | -394.09M |
| Gritstone Bio Inc | -121.65M |